Christopher J. Logothetis

Mar 26, 2024 | europeanurology.com | Christopher J. Logothetis |Andrew Hahn

We appreciate the insights that Dr. Wassersug and his team highlight in their letter on our paper [ [1] Logothetis CJ, Hahn AW. Challenging the prevailing therapeutic dogma for prostate cancer: the case for an overlap syndrome. Eur Urol. In press. http://doi.org/10.1016/j.eururo.2023.04.015. ], which aims to shed light on the concept of an “overlap syndrome” and emphasize the importance of estradiol (E2) in the context of this syndrome.